

---

# Drugs Which May Exacerbate or Induce Myasthenia Gravis: A Clinician's Guide

A Ahmed, Z Simmons

---

## Citation

A Ahmed, Z Simmons. *Drugs Which May Exacerbate or Induce Myasthenia Gravis: A Clinician's Guide*. The Internet Journal of Neurology. 2008 Volume 10 Number 2.

## Abstract

When a patient develops an exacerbation of myasthenia gravis, the treating physician searches for possible causes. One such cause is the prescription of one or more medications which may worsen neuromuscular transmission. Clinicians should be aware not only of the specific medications which may produce such exacerbations, but also of the probability of exacerbations with specific medications, so that they can balance the potential for good and the potential for harm in order to arrive at a reasonable therapeutic plan. An awareness of medications which may trigger myasthenia gravis in patients with no history of this disorder is important as well, particularly for neurologists who are asked to evaluate such patients. For those patients with myasthenia gravis undergoing anesthesia, anesthesiologists should be aware of anesthetic agents which warrant special attention.

## INTRODUCTION

Myasthenia gravis is an immune-mediated post-synaptic disorder of neuromuscular transmission, most commonly presenting as oculobulbar and proximal muscle weakness associated with easy fatigability. Because a variety of pharmacologic agents may affect neuromuscular transmission, physicians caring for these patients often must determine whether the medications needed by these patients are likely to adversely affect their myasthenia gravis. This is a particularly important question when such medications are being prescribed for potentially life-threatening conditions such as cardiac arrhythmias, or when anesthetic agents must be chosen for life-saving surgery. In addition, many patients with myasthenia gravis are treated with immunosuppressive agents, leading to more frequent and serious infections than are seen in the general population, and requiring judicious choices of antibiotics. The purpose of this review is to provide a clinician's guide to medications which may exacerbate myasthenia gravis, or which may produce signs and symptoms of myasthenia gravis in patients without a known defect of neuromuscular transmission. We also call attention to special considerations regarding the use of anesthetic agents in these patients. This is not intended as a comprehensive review of pharmacologic mechanisms, but rather as a practical, concise summary of drugs which should be of use to specialists and generalists alike.

## CALCIUM CHANNEL BLOCKERS

The mechanism by which calcium channel blockers affect neuromuscular transmission is not well established. They are believed to act at both the presynaptic and postsynaptic levels via blockade of L-type calcium channels.<sup>1,2</sup> Verapamil also prevents potassium outflow at the motor end plate and causes a decrease in intracellular ionized calcium levels.<sup>3</sup> In patients without known defects of neuromuscular transmission, the calcium channel blockers felodipine and nifedipine have been found to produce features of myasthenia gravis including dysphagia, ptosis, and generalized weakness after long-term use ranging from 18 months to 12 years. These patients were seronegative for acetylcholine receptor antibodies but demonstrated decremental responses on repetitive nerve stimulation. Discontinuing these drugs resulted in resolution of their symptoms, which re-appeared after the medications were reintroduced.<sup>1</sup> Similarly, oral use of verapamil and amlodipine for at least 3 months in patients with no prior known neuromuscular junction defects has resulted in abnormal jitter on single-fiber EMG study.<sup>2</sup> In patients with known myasthenia gravis, nifedipine caused worsening of symptoms.<sup>4</sup> In contrast, short term use of verapamil did not worsen the decrement seen on repetitive nerve stimulation when given to patients with myasthenia gravis as a single injection or when given orally for 14 days.<sup>5,6</sup> Thus, although not absolutely contraindicated, calcium channel blockers

should be used with caution in patients with myasthenia gravis. Short term use appears to be less risky than long term use.

### BETA BLOCKERS

Case reports describe a number of beta blockers, including propranolol, practolol, oxprenolol, atenolol, sotalol, nadolol, and ophthalmic timolol which appear to have produced symptoms and signs of myasthenia gravis in patients with no known defects of neuromuscular transmission, or to have exacerbated myasthenic symptoms in patients with known myasthenia gravis.<sup>7,8,9,10,11</sup> Findings have included ptosis, diplopia, and decremental responses on repetitive stimulation studies. The mechanism may be at the level of the neuromuscular junction or the muscle membrane.<sup>7,8</sup> Recovery has followed discontinuation of these medications.<sup>7,8,10,11</sup> Doses have varied widely, and no clear dose-response relationships with severity of symptoms of myasthenia gravis have been established. As with calcium channel blockers, short term use of propranolol intravenously as a single dose, or orally for 14 days has not been found to worsen the decremental response on repetitive stimulation in patients with known myasthenia gravis.<sup>5,6</sup> We believe that chronic use of beta blockers must be undertaken with great caution in patients with myasthenia gravis, whereas short-term use appears to be less risky.

### ANTI-ARRHYTHMIC AGENTS

Anti-arrhythmic agents including procainamide, etafenone, peruvoside, and propafenone have been reported to both induce and exacerbate myasthenia gravis. Descriptions consist primarily of case reports<sup>12,13,14,15</sup>. Procainamide is believed to act both pre-synaptically and post-synaptically,<sup>12,13,16</sup> decreasing the release of acetylcholine<sup>12</sup> and reducing the susceptibility of the muscle membrane to action potentials.<sup>12,13</sup> Propafenone and procainamide appear to act as sodium influx blockers.<sup>12,15</sup> Myasthenic symptoms were seen with acute and chronic use; the duration of treatment ranging from a few hours to 8 months before development of symptoms. Drug levels and dosages varied, as with beta blockers. Caution and close observation are needed if these medications must be used for short-term or long-term therapy in patients with myasthenia gravis.

### QUINOLONE DERIVATIVES

Quinine, quinidine, and chloroquine affect neuromuscular transmission both presynaptically and post synaptically.<sup>17,18</sup> At the presynaptic level there is a reduction of acetylcholine release due to blockade of voltage dependent sodium

channels,<sup>18</sup> and postsynaptically there is potentiation of depolarization.<sup>17</sup> Some patients with no evidence of a pre-existing neuromuscular junction disorder developed ptosis, diplopia, dysarthria, dysphagia, and generalized weakness while taking chloroquine.<sup>19,20,21</sup> Single-fiber EMG study or repetitive stimulation studies were abnormal. Clinical and electrodiagnostic abnormalities resolved with discontinuation of the medication. Some reports have found that acetylcholine receptor antibodies were absent in such patients.<sup>17,19,21</sup> Others have noted these and other antibodies such as anti-DNA and anti nuclear antibodies to be present, but to disappear after discontinuation of these medications.<sup>20</sup> Thus, quinolone derivatives, like many of the medications discussed here, must be used with caution in patients with known myasthenia gravis. In addition, the treating physician should be alert to the possibility of the development of symptoms of myasthenia gravis in patients treated with these medications who have no known history of this condition.

### PENICILLAMINE

Penicillamine is used for treatment of a variety of autoimmune disorders, and may be associated with the development of myasthenic symptoms including diplopia, dysarthria, and ptosis, in association with elevated titers of acetylcholine receptor antibodies.<sup>22</sup> Multiple mechanisms are thought to contribute to development of myasthenia. Some of these patients may have autoimmune-mediated subclinical defects of neuromuscular transmission which are unmasked by penicillamine.<sup>3,23,24,25,26</sup> Another potential mechanism is a direct immunomodulating effect of the drug by binding to the acetylcholine receptors with resultant production of antibodies directed against the receptors.<sup>27</sup> Prostaglandin E1 induced muscle weakness has also been postulated.<sup>28</sup> Generally complete resolution of these symptoms and disappearance of acetylcholine receptor antibodies occurs with discontinuation of the penicillamine.<sup>27,29,30,31</sup> Most reports of penicillamine-associated myasthenia gravis involve long term therapy, typically 2 months to 2 years.<sup>27,30</sup> Penicillamine can be used with caution and close monitoring in patients with myasthenia gravis.

### CORTICOSTEROIDS

Corticosteroids are considered to be effective treatment for myasthenia gravis, due to their immunosuppressive action which includes decreasing lymphocyte activation and migration.<sup>32,33,34</sup> However, steroids can worsen muscle strength acutely,<sup>35,36,37,38</sup> likely due to a direct blocking effect on the acetylcholine receptor through ionic channels<sup>39</sup>

or an effect on muscle contractility.<sup>39</sup> Decreased protein synthesis and myosin loss have been identified in patients who weaken with steroids.<sup>40</sup> Steroid-induced exacerbations of myasthenia gravis are more likely in older patients with bulbar symptoms.<sup>34</sup> With long term use, steroid myopathy may result.<sup>33</sup>

## **H-2 RECEPTOR ANTAGONISTS**

Animal studies report neuromuscular transmission abnormalities with H-2 receptor blockers such as cimetidine, ranitidine, and roxatidine.<sup>41,42,43</sup> Postulated mechanisms include pre-synaptic and post-synaptic interactions<sup>43</sup> and inhibition of acetylcholinesterase,<sup>43</sup> however there are no convincing reports of induction or exacerbation of myasthenia gravis in humans. Caution should be exercised when using these agents in individuals with myasthenia gravis, but they are not contra-indicated.

## **ANTIBIOTICS**

Both induction and exacerbation of myasthenia gravis can occur with the use of some antibiotics. In addition, other medical conditions that frequently occur in the setting of antibiotic use such as surgery, the administration of muscle relaxants, and the presence of other debilitating diseases can contribute to impaired neuromuscular transmission.<sup>44,45</sup>

### **Aminoglycosides**

These are perhaps the most well-known antibiotic agents associated with neuromuscular transmission abnormalities, regardless of route of administration.<sup>25,44</sup> They appear to act via a wide range of pre-synaptic and post-synaptic mechanisms. Streptomycin can block the acetylcholine receptor and can also prevent the release of acetylcholine.<sup>46,47</sup> Neomycin is thought to act through ionic channels and block the acetylcholine receptors.<sup>46</sup> Kanamycin, clindamycin, and lincomycin are considered to act postsynaptically.<sup>47</sup> Gentamycin, tobramycin and amikacin are thought to affect the presynaptic release of acetylcholine.<sup>47,48</sup> The neuromuscular transmission defect is generally reversed by calcium and/or neostigmine.<sup>47</sup>

### **MACROLIDES**

Erythromycin may affect neuromuscular transmission by acting presynaptically,<sup>48</sup> and so may produce or worsen symptoms of myasthenia gravis in patients with pre-existing post-synaptic defects.<sup>48</sup> Exacerbations of myasthenia gravis have been reported with the use of telithromycin<sup>49,50</sup> and azithromycin.<sup>51</sup> Fluoroquinolones

This category consists of a large number of antibiotics, including ciprofloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and trovafloxacin. These have been reported to cause neuromuscular transmission defects,<sup>3,52</sup> although the exact mechanisms are not known. Others

A few cases of worsening of myasthenic symptoms have been observed with the use of ampicillin<sup>53</sup> and other penicillins. Bacitracin may also worsen myasthenia, but the literature is confounded by the concomitant use of other antibiotics.<sup>47</sup> Polymyxins are considered to act both pre- and post-synaptically to produce or exacerbate myasthenia gravis.<sup>25</sup> Their action is reversed by the administration of diaminopyridine only.<sup>47</sup> Tetracycline and its analogues are reported to have weak neuromuscular blocking effects which usually are reversed by calcium,<sup>47</sup> and are thought to exacerbate myasthenia gravis.<sup>23,25</sup> There have been reports of worsening of myasthenia with the use of imipenem/cilastatin,<sup>54</sup> and with infusion of vancomycin.<sup>55</sup> The mechanism of action of these at the neuromuscular junction is not known.

We recommend avoiding the use of aminoglycosides in patients with known neuromuscular transmission defects. The other antibiotics discussed above should be used with caution in these patients.

## **ANTIEPILEPTICS**

Case reports and animal studies report unmasking and induction of myasthenic symptoms with the use of phenytoin, carbamazepine, trimethadione and gabapentin.<sup>56,57,58,59</sup> A variety of mechanisms have been identified. Long term phenytoin use may cause a depressed postsynaptic response to acetylcholine, inhibition at the level of calcium channels, and (at high concentration) an increase in the threshold of the muscle membrane.<sup>60</sup> Carbamazepine and trimethadione are thought to trigger an immune response with development of myasthenic symptoms.<sup>58,61,62,63</sup> Unmasking of myasthenia gravis is seen with the use of gabapentin, which is thought to bind to voltage gated calcium channels.<sup>59</sup> Remission is generally seen after withdrawal of these drugs. While none of these medications commonly unmask or induce myasthenia gravis, physicians should be aware of the possibility.

## **MISCELLANEOUS DRUGS THAT MAY WORSEN OR INDUCE MYASTHENIA GRAVIS**

## **CHEMOTHERAPEUTIC AGENTS**

The chemotherapeutic agents doxorubicin, etoposide, and cisplatin have been reported to exacerbate myasthenia gravis.<sup>64,65</sup> Respiratory and bulbar dysfunction have been noted within 24 hours of receiving these agents in combination, but cisplatin alone has been associated with respiratory worsening. The mechanism at the neuromuscular junction is unknown.

## **INTERFERON**

The use of interferon alpha and beta for hepatitis C and multiple sclerosis has been associated with the development and exacerbation of a variety of myasthenic symptoms including ptosis, diplopia, dysarthria, and weakness, from one week to one year after beginning interferon treatment.<sup>66,67,68,69,70</sup> Elevated titers of acetylcholine receptor antibodies and decremental responses on repetitive nerve stimulation have been noted.<sup>66</sup> The mechanism appears to be autoantibody production,<sup>66</sup> and acetylcholine receptor antibodies have been found to persist even after discontinuation of interferon. The development of clinical findings of myasthenia gravis is not inevitable in patients undergoing interferon treatment. A patient with multiple sclerosis has been described who was seropositive but asymptomatic for myasthenia gravis, and who remained asymptomatic when treated with interferon.<sup>71</sup> It appears that interferon can be used in some individuals with myasthenia gravis, but the physician should be aware of the possibility of an exacerbation. Psychotropic medications

Lithium use can induce and unmask myasthenic symptoms. The mechanism is thought to be a decrease in the synthesis of acetylcholine and increased breakdown of acetylcholine receptors.<sup>56,72</sup> Lithium can also prolong neuromuscular blockade caused by neuromuscular blocking anesthetics.<sup>25,44</sup> Neuroleptics such as chlorpromazine and haloperidol, and tricyclic antidepressants such as amitriptyline and imipramine, are considered to have an adverse effect on neuromuscular transmission.<sup>23,73</sup> Caution should be exercised with the use of these psychotropic medications in myasthenic patients.

## **ANTHELMINTICS**

There is a case report of the antihelminthic drug pyrantel pamoate causing worsening of myasthenic symptoms.<sup>74</sup>

## **SPECIAL CONSIDERATIONS -ANESTHETICS**

There are some special considerations when using anesthetic agents in patients with myasthenia gravis. These vary

depending on the class of agent. Neuromuscular blockers

Post-synaptic blockade is caused by depolarizing and nondepolarizing anesthetics. Patients with defects of neuromuscular transmission are particularly sensitive to nondepolarizing drugs<sup>75</sup> including atracurium, cisatracurium, doxacurium, gallamine, mivacurium, pancuronium, pipecuronium, rocuronium, tubocurarine, and vecuronium. Patients with fewer acetylcholine receptors such as myasthenics will show a rapid and marked neuromuscular blockade.<sup>75,76</sup> Another factor to consider is the inhibition of metabolism of some of these agents by pyridostigmine which may delay the recovery time.<sup>75</sup> In contrast, higher doses of depolarizing agents (succinylcholine, suxamethonium) are needed in myasthenic patients than in normal subjects.<sup>77</sup> Inhaled anesthetics

Agents such as sevoflurane, isoflurane, desflurane, halothane, enflurane, and nitrous oxide are used for intubation as well as maintenance of anesthesia.<sup>78,79</sup> Myasthenic patients require smaller amounts of these agents than normal, but the effects on neuromuscular transmission do not extend beyond the discontinuation of the agent, thus permitting rapid post-operative extubation of patients with myasthenia gravis.<sup>79</sup>

## **INTRAVENOUS ANESTHETICS**

Drugs such as propofol<sup>79</sup> and opioids in therapeutic concentrations are considered to be safe for patients with defects of neuromuscular transmission.<sup>75</sup> Local anesthetics

Local anesthetics such as lidocaine, procaine, bupivacaine and ester anesthetics are thought to potentiate the effects of neuromuscular blocking agents.<sup>25,75</sup> However, the use of reduced dosages in myasthenic patients can decrease the chance of complications.

**Figure 1**

Table 1: Medications which may exacerbate myasthenia gravis or induce symptoms of myasthenia gravis in asymptomatic individuals (see text for details)

Drug Class	Specific Drugs
Calcium channel blockers:	Amlodipine Felodipine Nifedipine Verapamil
Beta Blockers:	Atenolol Nadolol Oxprenolol Practolol Propranolol Sotalol Timolol-ophthalmic soln.
Anti-Arrhythmic agents:	Etafenone Peruvoside Procainamide Propafenone
Quinolone Derivatives:	Chloroquine Quinidine Quinine
Penicillamine	
Corticosteroids:	Hydrocortisone Methylprednisolone Prednisolone Prednisone
H-2 receptor antagonists:	Cimetidine Ranitidine Roxatidine
Antibiotics -Aminoglycosides	Amikacin Clindamycin Gentamycin Kanamycin Lincomycin Neomycin Streptomycin Tobramycin
Antibiotics -Macrolides	Azithromycin Erythromycin Telithromycin
Antibiotics -Fluoroquinolones	Ciprofloxacin Levofloxacin Moxifloxacin Gemifloxacin Lomefloxacin
	Norfloxacin Ofloxacin Trovafloxacin
Antibiotics -Penicillins/Ampicillin	
Antibiotics -Polymyzans	
Antibiotics -Tetracyclines	
Antibiotics -Imipenem/Cisastatin	
Antibiotics -Vancomycin	
Antiepileptics:	Carbamazepine Gabapentin Phenytoin Trimethadione
Chemotherapeutic agents:	Cisplatin Doxorubicin Etoposide
Interferons:	Alpha and beta
Psychotropic medications:	Chlorpromazine Haloperidol Lithium Tricyclic antidepressants
Antihelmintics	Pyrantel pamoate

**Figure 2**

Table 2: Anesthetic agents which should be used with caution in patients with myasthenia gravis (see text for details)

Class of anesthetic agent	Specific anesthetic agent
Non-depolarizing neuromuscular blockers	Atracurium Cisatracurium Gallamine Doxacurium Mivacurium Pancuronium Pipecuronium Rocuronium Tubocurarine Vecuronium
Depolarizing neuromuscular blockers	Succinylcholine Suxamethonium
Inhaled	Desflurane Enflurane Halothane Isoflurane Nitrous oxide Sevoflurane
	Opioids
Intravenous	Propofol
Local	Bupivacaine Esther anesthetics Lidocaine Procaine

**CONCLUSIONS**

Many medications have been implicated as possibly worsening myasthenia gravis or inducing symptoms of myasthenia gravis in asymptomatic individuals. These are summarized in Table 1. Most of the data is in the form of case reports or very small series, making firm recommendations challenging. With the likely exception of aminoglycoside antibiotics, most other agents discussed in this review can be used in patients with myasthenia gravis if medically indicated, but should be employed with caution and close monitoring. In addition, anesthetic agents must be used with caution in these patients (Table 2). An awareness of the potential for exacerbating or inducing symptoms of myasthenia gravis should permit clinicians to engage in safer treatment of medical and surgical problems in these patients.

**References**

1. Pina Latorre MA, Cobeta JC, Rodilla F, et al. Influence of calcium antagonist drugs in myasthenia gravis in the elderly. *J Clin Pharm Ther* 1998;23:399-401.
2. Ozkul Y. Influence of calcium channel blocker drugs in neuromuscular transmission. *Clin Neurophysiol* 2007;118:2005-2008.
3. Wittbrodt ET. Drugs and myasthenia gravis. An update. *Arch Intern Med* 1997;157:399-408.
4. Rajasekaran D, Chandrasekar S, Rajendran M. Drug related crisis in myasthenia gravis. *J Assoc Physicians India* 2006;54:820-821.
5. Matell G, Bjelak S, Jonkers I, et al. Calcium channel and beta-receptor antagonists and agonists in MG. *Ann N Y Acad Sci* 1998;841:785-788.
6. Jonkers I, Swerup C, Pirskanen R, et al. Acute effects of intravenous injection of beta-adrenoreceptor-and calcium channel at antagonists and agonists in myasthenia gravis. *Muscle Nerve* 1996;19:959-965.
7. Herishanu Y, Rosenberg P. Letter: Beta-blockers and

- myasthenia gravis. *Ann Intern Med* 1975;83:834-835.
8. Weber JC. Beta-adrenoreceptor antagonists and diplopia. *Lancet* 1982;2(8302):826-827.
9. Choi KL, Wat MS, Kung AW, et al. Pheochromocytoma associated with myasthenia gravis precipitated by propranolol treatment. *Aust N Z J Med* 1995;25:257.
10. Hughes RO, Zacharias FJ. Letter: Myasthenic syndrome during treatment with practolol. *Br Med J* 1976;1(6007):460-461.
11. Shaivitz SA. Timolol and myasthenia gravis. *JAMA* 1979;242:1611-1612.
12. Miller CD, Oleshansky MA, Gibson KF, et al. Procainamide-induced myasthenia-like weakness and dysphagia. *Ther Drug Monit* 1993;15:251-254.
13. Godley PJ, Morton TA, Karboski JA, et al. Procainamide-induced myasthenic crisis. *Ther Drug Monit* 1990;12:411-414.
14. Niakan E, Bertorini TE, Acchiardo SR, et al. Procainamide-induced myasthenia-like weakness in a patient with peripheral neuropathy. *Arch Neurol* 1981;38:378-379.
15. Lecky BR, Weir D, Chong E. Exacerbation of myasthenia by propafenone. *J Neurol Neurosurg Psychiatry* 1991;54:377.
16. Fierro B, Castiglione MG, Salemi G, et al. Myasthenia-like syndrome induced by cardiovascular agents. Report of a case. *Ital J Neurol Sci* 1987;8:167-169.
17. Robberecht W, Bednarik J, Bourgeois P, et al. Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. *Arch Neurol* 1989;46:464-468.
18. Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. *Brain Res* 1996;712:179-189.
19. Klimek A. The myasthenic syndrome after chloroquine. *Neurol Neurochir Pol* 1999;33:951-954.
20. Sghirlanzoni A, Mantegazza R, Mora M, et al. Chloroquine myopathy and myasthenia-like syndrome. *Muscle Nerve* 1988;11:114-119.
21. Bruggemann W, Herath H, Ferbert A. Follow-up and immunologic findings in drug-induced myasthenia. *Med Klin* 1996;91:268-271.
22. Penn AS, Low BW, Jaffe IA, et al. Drug-induced autoimmune myasthenia gravis. *Ann N Y Acad Sci* 1998;841:433-449.
23. Adams SL, Mathews J, Grammer LC. Drugs that may exacerbate myasthenia gravis. *Ann Emerg Med* 1984;13:532-538.
24. Jan V, Callens A, Machet L, et al. D-penicillamine-induced pemphigus, polymyositis and myasthenia. *Ann Dermatol Venereol* 1999;126:153-156.
25. Howard JF Jr. Adverse drug effects on neuromuscular transmission. *Semin Neurol* 1990;10:89-102. -- a. 26. Komal Kumar RN, Patil SA, Taly AB, et al. Effect of d-penicillamine on neuromuscular junction in patients with Wilson disease. *Neurolog*.2004;63:935 -- b. 936.
26. Drosos AA, Christou L, Galanopoulou V, et al. D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings. *Clin Exp Rheumatol* 1993;11:387-391.
27. Horrobin DF. Myasthenia and prostaglandin E1. *Ann Intern Med* 1979;90:719.
28. Kuncl RW, Pestronk A, Drachman DB, et al. The pathophysiology of penicillamine-induced myasthenia gravis. *Ann Neurol* 1986;20:740-744.
29. Raynauld JP, Lee YS, Kornfeld P, et al. Unilateral ptosis as an initial manifestation of D-penicillamine induced myasthenia gravis. *J Rheumatol* 1993;20:1592-1593.
30. Adelman HM, Winters PR, Mahan CS, et al. D-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary disease. *Am J Med Sci* 1995;309:191-193.
31. Abramsky O, Aharonov A, Teitelbaum D, et al. Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. *Arch Neurol* 1975;32:684-687.
32. Vallet B, Fourrier F, Hurtevent JF, et al. Myasthenia gravis and steroid-induced myopathy of the respiratory muscles. *Intensive Care Med* 1992;18:424-426.
33. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. *Journal of Clinical Neuroscience* 2006;13:1006-1010.
34. Patten BM, Oliver KL, Engel WK. Adverse interaction between corticosteroid hormones and anticholinesterase drugs. *Trans Am Neurol Assoc* 1973;98:248-252.
35. Brunner NG, Namba T, Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. *Neurology* 1972;22:603-610.
36. Jenkins RB. Treatment of myasthenia gravis with prednisone. *Lancet* 1972;1(7754):765-767.
37. Karcic AA. Drugs that can worsen myasthenia gravis.[comment]. *Postgrad Med* 2000;108:25.
38. Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. *Neurolog* 1986;36:729-732.
39. Panegyres PK, Squier M, Mills KR, et al. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. *J Neurol Neurosurg Psychiatry* 1993;56:702-704.
40. Bossa R, Chiericozzi M, Galatulas I, et al. The effects of roxatidine on neuromuscular transmission. *In Vivo* 1995;9:113-115.
41. Bossa R, Chiericozzi M, Efstathiou G, et al. The effect of H2 receptor antagonists on neuromuscular transmission. *In Vivo* 1991;5:57-59. -- a. 43. Re L, Di Sarra B. Effects of famotidine at the mouse neuromuscular junction compared with those of cimetidine and ranitidine. *Pharmacology* 1989;39:200 -- b. 204.
42. Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. *Pharmacotherapy* 1997;17:1220-1232.
43. McQuillen MP. Hazard from antibiotics in myasthenia gravis. *Ann Intern Med* 1970;73:487-488.
44. Fiekers JF. Effects of the aminoglycoside antibiotics, streptomycin and neomycin, on neuromuscular transmission. II. Postsynaptic considerations. *J Pharmacol Exp Ther* 1983;225:496-502.
45. Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. *Anesthesiology* 1981;55:148-159.
46. May EF, Calvert PC. Aggravation of myasthenia gravis by erythromycin. *Ann Neurol* 1990;28:577-579.
47. Perrot X, Bernard N, Vial C, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. *Neurology* 2006;67:2256-2258.
48. Jennett AM, Bali D, Jasti P, et al. Telithromycin and myasthenic crisis.[comment]. *Clin Infect Dis* 2006;43:1621-1622.
49. Cadisch R, Streit E, Hartmann K. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)]. *Schweizerische Medizinische Wochenschrift Journal Suisse de Medecine* 1996;126:308-310.
50. Gunduz A, Turedi S, Kalkan A, et al. Levofloxacin induced myasthenia crisis. *Emerg Med J* 2006;23:662.
51. Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. *Arch Neurol* 1986;43:255-256.
52. O'Riordan J, Javed M, Doherty C, et al. Worsening of myasthenia gravis on treatment with imipenem/cilastatin. *J*

- Neurol Neurosurg Psychiatry 1994;57:383.
52. Huang KC, Heise A, Shrader AK, et al. Vancomycin enhances the neuromuscular blockade of vecuronium. *Anesth Analg* 1990;71:194-196.
53. Kaeser HE. Drug-induced myasthenic syndromes. *Acta Neurol Scand Suppl* 1984;100:39-47.
54. Ozawa T, Nakajima T, Furui E, et al. A case of myasthenia gravis associated with long-term phenytoin therapy. *Rinsho Shinkeigaku* 1996;36:1262-1264.
55. Booker HE, Chun RW, Sanguino M. Myasthenia gravis syndrome associated with trimethadione. *JAMA* 1970;212:2262-2263.
56. Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. *Muscle Nerve* 2000;23:1204-1208.
57. So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. *Epilepsia* 1981;22:467-473.
58. Kurian MA, King MD. Antibody positive myasthenia gravis following treatment with carbamazepine--a chance association? *Neuropediatrics* 2003;34:276-277.
59. Rasmussen M. Carbamazepine and myasthenia gravis. *Neuropediatrics* 2004;35:259.
60. Peterson H. Association of trimethadione therapy and myasthenia gravis. *N Engl J Med* 1966;274:506-507.
61. Solak Y, Dikbas O, Altundag K, et al. Myasthenic crisis following cisplatin chemotherapy in a patient with malignant thymoma. *J Exp Clin Cancer Res* 2004;23:343-344.
62. Ng CV. Myasthenia gravis and a rare complication of chemotherapy. *Med J Aust* 2005;182:120.
63. Weegink CJ, Chamuleau RA, Reesink HW, et al. Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. *J Gastroenterol* 2001;36:723-724.
64. Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. *Neurology* 1997;49:1747-1748.
65. Dionisiotis J, Zoukos Y, Thomaidis T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment. *J Neurol Neurosurg Psychiatry* 2004;75:1079.
66. Harada H, Tamaoka A, Kohno Y, et al. Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. *J Neurol Sci* 1999;165:182-183.
67. Borgia G, Reynaud L, Gentile I, et al. Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C. *J Interferon Cytokine Res* 2001;21:469-470.
68. Shimizu H, Kataoka H, Kawahara M, et al. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis. *Clin Neurol Neurosurg* 2007;109:277-278.
69. Alevizos B, Gatzonis S, Anagnostara C. Myasthenia gravis disclosed by lithium carbonate. *J Neuropsychiatry Clin Neurosci* 2006;18:427-429.
70. Argov Z, Mastaglia FL. Drug therapy: Disorders of neuromuscular transmission caused by drugs. *N Engl J Med* 1979;301:409-413.
71. Bescansa E, Nicolas M, Aguado C, et al. Myasthenia gravis aggravated by pyrantel pamoate. *J Neurol Neurosurg Psychiatry* 1991;54:563.
72. Abel M, Eisenkraft JB. Anesthetic implications of myasthenia gravis. *Mt Sinai J Med* 2002;69:31-37.
73. Baraka A. Onset of neuromuscular block in myasthenic patients. *Br J Anaesth* 1992;69:227-228.
74. Levitan R. Safety of succinylcholine in myasthenia gravis. *Ann Emerg Med* 2005;45:225-226.
75. Baraka A. Anesthesia and critical care of thymectomy for myasthenia gravis. *Chest Surg Clin N Am* 2001;11:337-361.
76. Della Rocca G, Coccia C, Diana L, et al. Propofol or sevoflurane anesthesia without muscle relaxants allow the early extubation of myasthenic patients. *Can J Anaesth* 2003;50:547-552.

**Author Information**

**A. Ahmed**

Department of Neurology, Penn State College of Medicine

**Z. Simmons**

Department of Neurology, Penn State College of Medicine